BEAM

20.8400.48%
GK

Graham K. Cooper

Independent Director

Mr. Graham K. Cooper, C.P.A., is CFO & COO of Tavo Biotherapeutics, Inc. Mr. Cooper served as Director at Applied Molecular Transport Inc., since February 5, 2020 until March 08, 2023 and served as its Executive Chairman since January 27, 2022 until March 08, 2023. He serves as Independent Director of Beam Therapeutics Inc. since October 8, 2019. He serves as Independent Director of Panacea Acquisition Corp., since July 2020. Mr. Cooper served as Chief Financial Officer and Chief Operating Officer at Assembly Biosciences, Inc. since March 8, 2018 until May 2019. Mr. Cooper served as the Chief Financial Officer of Receptos, Inc. (formerly Receptos Corporation) from February 14, 2013 to August 27, 2015. Mr. Cooper served as the Chief Financial Officer and Executive Vice President of Finance & Business Development at Geron Corporation from January 5, 2012 to December 7, 2012. From August 1992 to January 1995, he served as an Accountant of Deloitte & Touche. He served as the Chief Financial Officer of Orexigen Therapeutics, Inc. from May 24, 2006 to March 11, 2011 and served as its Treasurer from May 2006 to March 11, 2011 and Senior Vice President of Finance and Principal Accounting Officer until March 11, 2011. He served as an Independent Director of Kezar Life Sciences, Inc., since October 2017 until May 11, 2026 and also served as its Independent Chairman since May 11, 2022 until May 11, 2026. He served as Secretary of Orexigen Therapeutics, Inc. since May 2006. Mr. Cooper serves as the Chief Financial Officer of Tavo Biotherapeutics, Inc. Prior to Orexigen, Mr. Cooper served as Director of Health Investment Banking of Deutsche Bank Securities from 1999 to 2006. During his tenure at Deutsche Bank and its predecessor firm Alex. Brown & Sons, from August 1997 to February 2006, he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. He had been Director at Unity Biotechnology, Inc. since April 17, 2017 until May 2022. He served as a Non-Employee Director of Celladon Corporation (now a subsidiary of Eiger BioPharmaceuticals, Inc.) from September 2013 to March 2016. He received a Certified Public Accountant from American Institute of Certified Public Accountants. Mr. Cooper serves on the Board of Directors for Bioniz Therapeutics, Inc. He was a C.P.A. Mr. Cooper received a B.A. degree in Economics with highest distinction from University of California at Berkeley and an MBA from the Stanford Graduate School of Business.

Positions